Publications by authors named "Malcolm Ranson"

Claim this Profile
T
Temperature-Dependent Infrared Refractive Index of Polymers from a Calibrated Attenuated Total Reflection Infrared Measurement.
Md S Azam, Malcolm D Ranson, Dennis K Hore

Appl Spectrosc· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
T R Jeffry Evans, Emma Dean, L Rhoda Molife, Juanita Lopez, Malcolm Ranson

Br J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, Howard Burris, Angel Guerrero-Zotano, Malcolm Ranson

Cancer Chemother Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR T790M mutation testing within the osimertinib AURA Phase I study.
Simon Dearden, Helen Brown, Suzanne Jenkins, Kenneth S Thress, Mireille Cantarini, Malcolm Ranson

Lung Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
David Jamieson, Melanie J Griffin, Julieann Sludden, Yvette Drew, Nicola Cresti, Malcolm Ranson

Eur J Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
David Planchard, Kathryn H Brown, Dong-Wan Kim, Sang-We Kim, Yuichiro Ohe, Malcolm Ranson

Cancer Chemother Pharmacol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
Bristi Basu, Emma Dean, Martina Puglisi, Alastair Greystoke, Michael Ong, Malcolm Ranson

Clin Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Pasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, David Planchard, Yuichiro Ohe, Malcolm Ranson

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.
L Rhoda Molife, Emma Jane Dean, Montserrat Blanco-Codesido, Matthew G Krebs, Andre T Brunetto, Malcolm Richard Ranson

Clin Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Darren A E Cross, Susan E Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A Nebhan, Malcolm R Ranson

Cancer Discov· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Hilary Calvert, Chris Twelves, Malcolm Ranson, Ruth Plummer, Scott Fettner

Anticancer Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.
Kyaw L Aung, Emma Donald, Gillian Ellison, Sarah Bujac, Lynn Fletcher, Malcolm Ranson

J Mol Diagn· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Enriqueta Felip, Malcolm Ranson, Susana Cedrés, Emma Dean, Mike Brewster

Clin Lung Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of cell death applicable to early clinical trials.
Emma Dean, Alastair Greystoke, Malcolm Ranson, Caroline Dive

Exp Cell Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors.
Jin Li, Yanfei Liu, Jun Qian, Lennie Wu, John Kemp, Malcolm Ranson

Cancer Chemother Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Charles M Rudin, Christine L Hann, Edward B Garon, Moacyr Ribeiro de Oliveira, Philip D Bonomi, Malcolm R Ranson

Clin Cancer Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Matthew G Krebs, Jian-Mei Hou, Robert Sloane, Lee Lancashire, Lynsey Priest, Malcolm Ranson

J Thorac Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.
Azeem Saleem, Julian C Matthews, Malcolm Ranson, Sophie Callies, Valérie André

Theranostics· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Juan W Valle, Anne Armstrong, Chris Newman, Valery Alakhov, Grzegorz Pietrzynski, Malcolm Ranson

Invest New Drugs· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.
Matthew G Krebs, Robert Sloane, Lynsey Priest, Lee Lancashire, Jian-Mei Hou, Malcolm Ranson

J Clin Oncol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.
Emma J Dean, Jeff Cummings, Anne Roulston, Mark Berger, Malcolm Ranson

Neoplasia· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cells as a window on metastasis biology in lung cancer.
Jian-Mei Hou, Matthew Krebs, Tim Ward, Robert Sloane, Lynsey Priest, Malcolm Ranson

Am J Pathol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.
Denis C Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Ruth E Board, Andrew M Wardley, J Michael Dixon, Anne C Armstrong, Sacha Howell, Malcolm Ranson

Breast Cancer Res Treat· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis